Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.29
NAS:THRX's Cash to Debt is ranked higher than
58% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. NAS:THRX: 1.29 )
NAS:THRX' s 10-Year Cash to Debt Range
Min: 0.89   Max: No Debt
Current: 1.29

Equity to Asset 0.44
NAS:THRX's Equity to Asset is ranked higher than
58% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:THRX: 0.44 )
NAS:THRX' s 10-Year Equity to Asset Range
Min: -1.04   Max: 0.67
Current: 0.44

-1.04
0.67
F-Score: 3
Z-Score: 0.28
M-Score: -3.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3549.03
NAS:THRX's Operating margin (%) is ranked higher than
52% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. NAS:THRX: -3549.03 )
NAS:THRX' s 10-Year Operating margin (%) Range
Min: -53258.33   Max: -9.58
Current: -3549.03

-53258.33
-9.58
Net-margin (%) -3587.66
NAS:THRX's Net-margin (%) is ranked higher than
52% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. NAS:THRX: -3587.66 )
NAS:THRX' s 10-Year Net-margin (%) Range
Min: -50786.54   Max: -13.66
Current: -3587.66

-50786.54
-13.66
ROE (%) -57.07
NAS:THRX's ROE (%) is ranked higher than
60% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. NAS:THRX: -57.07 )
NAS:THRX' s 10-Year ROE (%) Range
Min: -262.27   Max: -11.96
Current: -57.07

-262.27
-11.96
ROA (%) -25.06
NAS:THRX's ROA (%) is ranked higher than
68% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. NAS:THRX: -25.06 )
NAS:THRX' s 10-Year ROA (%) Range
Min: -98.77   Max: -5.03
Current: -25.06

-98.77
-5.03
ROC (Joel Greenblatt) (%) -1649.37
NAS:THRX's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. NAS:THRX: -1649.37 )
NAS:THRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1649.37   Max: -142
Current: -1649.37

-1649.37
-142
Revenue Growth (%) -47.20
NAS:THRX's Revenue Growth (%) is ranked higher than
58% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. NAS:THRX: -47.20 )
NAS:THRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 125.7
Current: -47.2

0
125.7
EBITDA Growth (%) 14.50
NAS:THRX's EBITDA Growth (%) is ranked higher than
90% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NAS:THRX: 14.50 )
NAS:THRX' s 10-Year EBITDA Growth (%) Range
Min: -63.2   Max: 14.5
Current: 14.5

-63.2
14.5
EPS Growth (%) 12.90
NAS:THRX's EPS Growth (%) is ranked higher than
89% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. NAS:THRX: 12.90 )
NAS:THRX' s 10-Year EPS Growth (%) Range
Min: -47.1   Max: 12.9
Current: 12.9

-47.1
12.9
» NAS:THRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

THRX Guru Trades in Q2 2013

Jim Simons 594,320 sh (+144.25%)
Jean-Marie Eveillard 1,109,620 sh (+139.14%)
Seth Klarman 16,538,977 sh (+22.02%)
Louis Moore Bacon Sold Out
Jeremy Grantham 20,800 sh (-40.74%)
Steven Cohen 50,000 sh (-85.16%)
» More
Q3 2013

THRX Guru Trades in Q3 2013

Jeremy Grantham 54,440 sh (+161.73%)
Seth Klarman 18,510,371 sh (+11.92%)
Jean-Marie Eveillard 1,223,220 sh (+10.24%)
Jim Simons 458,320 sh (-22.88%)
Steven Cohen 23,500 sh (-53%)
» More
Q4 2013

THRX Guru Trades in Q4 2013

Louis Moore Bacon 50,000 sh (New)
Steven Cohen 35,120 sh (+49.45%)
Jeremy Grantham 72,694 sh (+33.53%)
Jean-Marie Eveillard 1,509,404 sh (+23.4%)
Seth Klarman 20,144,301 sh (+8.83%)
Jim Simons 493,020 sh (+7.57%)
» More
Q1 2014

THRX Guru Trades in Q1 2014

Chuck Royce 22,900 sh (New)
Jean-Marie Eveillard 1,595,520 sh (+5.71%)
Seth Klarman 20,705,801 sh (+2.79%)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Jeremy Grantham 32,200 sh (-55.7%)
Jim Simons 136,334 sh (-72.35%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:THRX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2014-03-31 Add 2.79%0.42%$24.31 - $32.63 $ 22-25%20705801
Seth Klarman 2013-12-31 Add 8.83%1.65%$27.19 - $32.81 $ 22-25%20144301
Jean-Marie Eveillard 2013-12-31 Add 23.4%0.03%$27.19 - $32.81 $ 22-25%1509404
Seth Klarman 2013-09-30 Add 11.92%2.3%$28.86 - $34.36 $ 22-29%18510371
Seth Klarman 2013-06-30 Add 22.02%2.85%$18.15 - $33.74 $ 22-18%16538977
Jean-Marie Eveillard 2013-06-30 Add 139.14%0.08%$18.15 - $33.74 $ 22-18%1109620
Jean-Marie Eveillard 2012-06-30 Add 24.23%0.01%$14.11 - $19.04 $ 2232%509710
Seth Klarman 2012-03-31 Add 2.3%0.22%$13.21 - $16.28 $ 2258%14553800
Jean-Marie Eveillard 2012-03-31 Add 25.59%0.01%$13.21 - $16.28 $ 2258%410310
Julian Robertson 2011-09-30 Sold Out 1.2512%$14.05 - $20.04 $ 2231%0
Seth Klarman 2011-09-30 Add 9.76%0.84%$14.05 - $20.04 $ 2231%14225961
Jean-Marie Eveillard 2011-06-30 Reduce -33.79%0.02%$17.07 - $23.13 $ 2210%326710
John Griffin 2011-06-30 Sold Out $17.07 - $23.13 $ 2210%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.50
NAS:THRX's P/B is ranked higher than
62% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. NAS:THRX: 9.50 )
NAS:THRX' s 10-Year P/B Range
Min: 3.71   Max: 265.49
Current: 9.5

3.71
265.49
P/S 666.67
NAS:THRX's P/S is ranked lower than
51% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. NAS:THRX: 666.67 )
NAS:THRX' s 10-Year P/S Range
Min: 0   Max: 798.5
Current: 666.67

0
798.5
EV-to-EBIT -11.93
NAS:THRX's EV-to-EBIT is ranked higher than
76% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NAS:THRX: -11.93 )
NAS:THRX' s 10-Year EV-to-EBIT Range
Min: 16.8   Max: 22.1
Current: -11.93

16.8
22.1
Current Ratio 8.82
NAS:THRX's Current Ratio is ranked higher than
87% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. NAS:THRX: 8.82 )
NAS:THRX' s 10-Year Current Ratio Range
Min: 2.41   Max: 16.1
Current: 8.82

2.41
16.1
Quick Ratio 8.57
NAS:THRX's Quick Ratio is ranked higher than
87% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. NAS:THRX: 8.57 )
NAS:THRX' s 10-Year Quick Ratio Range
Min: 2.41   Max: 15.83
Current: 8.57

2.41
15.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 84.60
NAS:THRX's Price/Net Cash is ranked higher than
72% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. NAS:THRX: 84.60 )
NAS:THRX' s 10-Year Price/Net Cash Range
Min: 4.74   Max: 829.43
Current: 84.6

4.74
829.43
Price/Net Current Asset Value 71.00
NAS:THRX's Price/Net Current Asset Value is ranked higher than
71% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. NAS:THRX: 71.00 )
NAS:THRX' s 10-Year Price/Net Current Asset Value Range
Min: 4.7   Max: 497.66
Current: 71

4.7
497.66
Price/Tangible Book 19.60
NAS:THRX's Price/Tangible Book is ranked higher than
61% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. NAS:THRX: 19.60 )
NAS:THRX' s 10-Year Price/Tangible Book Range
Min: 4.02   Max: 224.4
Current: 19.6

4.02
224.4
Price/Median PS Value 9.50
NAS:THRX's Price/Median PS Value is ranked higher than
58% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:THRX: 9.50 )
NAS:THRX' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 12.38
Current: 9.5

0.17
12.38
Forward Rate of Return (Yacktman) -17.31
NAS:THRX's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. NAS:THRX: -17.31 )
NAS:THRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.1   Max: -6.2
Current: -17.31

-8.1
-6.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HVE.Germany
Theravance Inc., was incorporated in Delaware in November 1996 under the name Advanced Medicine, Inc, and began operations in May 1997. The Company changed its name to Theravance, Inc. in April 2002. It is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical. The Company has determined that it operates in a single segment which is the discovery (research), development and commercialization of human therapeutics including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its key programs include: RELVAR or BREO (fluticasone furoate/vilanterol), ANORO (umeclidinium bromide/vilanterol) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc (GSK), and its oral Peripheral Mu Opioid. Its drug discovery efforts are based on the principles of multivalency. Multivalency involves the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets. The Company has applied its expertise in multivalency to discover product candidates and compounds in therapeutic areas. It has conducted research in both relevant laboratory and animal models to demonstrate that by applying the design principles of multivalency. Alhough it has limited in-house active pharmaceutical ingredient (API) production capabilities, the company relies on a number of third parties, including contract manufacturing organizations and its collaborative partners, to produce active pharmaceutical ingredient and drug product. As of December 31, 2012, the company owned 329 issued United States patents and 1,110 granted foreign patents. It competes with number of existing antibacterials manufactured and marketed by major pharmaceutical companies and others. The Company's product candidates are subject to regulation by governmental authorities in the United States and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide